Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007064521 - MORINDA CITRIFOLIA LEAF JUICE AND LEAF EXTRACT BASED FORMULATIONS

Publication Number WO/2007/064521
Publication Date 07.06.2007
International Application No. PCT/US2006/044949
International Filing Date 21.11.2006
IPC
A61K 36/746 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
74Rubiaceae (Madder family)
746Morinda
A61K 36/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
CPC
A61K 36/746
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
74Rubiaceae (Madder family)
746Morinda
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61P 13/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
08of the prostate
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
A61P 19/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
06Antigout agents, e.g. antihyperuricemic or uricosuric agents
A61P 25/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
04Centrally acting analgesics, e.g. opioids
Applicants
  • TAHITIAN NONI INTERNATIONAL, INC. [US]/[US] (AllExceptUS)
  • PALU, Afa, Kehaati [TO]/[TO] (UsOnly)
  • ZHOU, Bing-Nan [CN]/[CN] (UsOnly)
  • SU, Chen, Xing [US]/[US] (UsOnly)
  • JENSEN, Claude, Jarakae [US]/[US] (UsOnly)
  • WEST, Brett, Justin [US]/[US] (UsOnly)
  • STORY, Stephen, P. (UsOnly)
Inventors
  • PALU, Afa, Kehaati
  • ZHOU, Bing-Nan
  • SU, Chen, Xing
  • JENSEN, Claude, Jarakae
  • WEST, Brett, Justin
  • STORY, Stephen, P.
Agents
  • KRIEGER, Michael, F.
Priority Data
11/560,40716.11.2006US
60/740,61229.11.2005US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) MORINDA CITRIFOLIA LEAF JUICE AND LEAF EXTRACT BASED FORMULATIONS
(FR) FORMULATIONS A BASE D'EXTRAITS DE FEUILLES ET DE JUS DE FEUILLES DE MORINDA CITRIFOLIA
Abstract
(EN)
A method and composition for inhibiting certain enzymes, where such inhibition results in various health benefits is provided. More particularly, a method and composition using one or more of the following: Noni Leaf Extract; Noni Leaf Juice; and/or Roast Leaf to inhibit the following: HMG-CoA Reductase; Phosphodiesterases (3 and 4) PDE3 and PDE4; 5 -Lipoxygenase (LOX) and 15-LOX; Xanthine Oxidase (XO); Gamma Amino Butyric Acid (GABA) and the growth of the second most common human skin cancer cell line, is provided. Moreover, the foregoing enzymatic inhibitions result in: alleviating pain and inflammation; treating prostate cancers; lowering cholesterol levels; counteracting Diabetes Type II; maintaining the highest possible integrity of cellular interactions in the brain resulting in an undisturbed neural function, (i.e., neuroprotection); ameliorating the effects of asthma and allergies; improving energy; improving insulin secretion; decreasing kidney stone accumulation; alleviating the effects of gout; minimizing convulsions related to epilepsy and other seizure disorders; and providing palliative effects to those addicted to drugs.
(FR)
L'invention concerne un procédé et une composition destinés à inhiber certaines enzymes en vue de produire divers avantages sur la santé. Plus particulièrement, l'invention concerne un procédé et une composition faisant intervenir au moins l'un de ces composants: extrait de feuilles de noni; jus de feuilles de noni; et/ou feuilles torréfiées pour inhiber les enzymes suivantes: HMG-CoA Réductase; Phosphodiestérases (3 et 4), PDE3 et PDE4; 5 -Lipoxygénase (LOX) et 15-LOX; Xanthine Oxydase (XO); acide gamma-amino butyrique (GABA), ainsi que la croissance de la deuxième lignée cellulaire la plus répandue du cancer de la peau chez l'homme. Par ailleurs, le résultat des inhibitions enzymatiques précitées a pour effet de : soulager la douleur et l'inflammation; traiter le cancer de la prostate; baisser le taux de cholestérol; contrebalancer les effets du diabète de Type II; maintenir l'intégrité de interactions cérébrales au plus haut niveau possible pour garantir une fonction neuronale continue (soit, la neuroprotection); améliorer les symptômes de l'asthme et des allergies; stimuler l'énergie; stimuler la sécrétion d'insuline; réduire la formation de calculs rénaux; soulager les symptômes de la goutte; réduire au minimum les convulsions liées à l'épilepsie et à d'autres troubles survenant par crises; et enfin, assurer des effets palliatifs aux toxicomanes.
Latest bibliographic data on file with the International Bureau